Louvain-la-Neuve, Belgium, 23 May 2024 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its business update for the first quarter ending 31 March 2024.
Group Overview
Good Group order intake at end of March, driven by continued growth in Other Accelerators, with typical strong second half weighting expected
Group backlog remains at a high of EUR 1.4 billion
EUR 30.1 million net cash position, decreasing as a result of a planned procurement of inventory, related to backlog conversion and among others the ten-room Proteus®ONE1 contract in Spain
B Corp certification renewed with a significantly improved score of 114 points (2021: 90 points), placing the Group among the top 10% of those certified globally
Olivier Legrain, Chief Executive Officer of IBA commented: “IBA has had a solid start to the year with a core focus on backlog execution and unlocking future growth potential. We continue to invest for growth and to maintain our leading edge across all of our businesses. We do expect a typical second half weighting both in terms of backlog conversion and order intake, supported by the opportunities in our pipeline.”
Proton Therapy
34 projects ongoing, with nine Proteus®PLUS1 and 25 Proteus®ONE systems in progress
Two customer shipments were completed during the period in Europe and the US
Post period-end contract signed with Yale New Haven Health and Hartford HealthCare for the installation of a Proteus®ONE proton therapy solution in Connecticut, USA
Dosimetry
Dosimetry order intake of EUR 18.6 million, broadly in line with Q1 2023
Acquisition of Radcal Corporation completed at end of period, expanding medical imaging offering and US presence
Other Accelerators (RadioPharma Solutions, Industrial Solutions)
Eight Other Accelerators sold during the reporting period (Q1 2023: four machines sold) with two more post-period, including a Cyclone® IKON contract signed in Asia
PanTera continues to progress plans for expansion of actinium-225 (225Ac) production with the construction of its early supply facility ongoing, plans for its commercial supply facility on track and new agreements signed with two additional pharmaceutical companies for early supply of 225Ac
Outlook
IBA has continued to deliver a solid performance over the first quarter across all business units. Alongside good overall order intake for the year to date, IBA is encouraged by its strong pipeline of active leads in all of its businesses. IBA expects 2024 performance to be strongly second half weighted as in previous years and reiterates its mid-term guidance detailed in its full-year 2023 results.